Overview

hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
There have been some controversies regarding the use of preparations with LH activity in patients with polycystic ovary syndrome (PCOS) who have high endogenous LH activity. In this research we aimed to compare urinary menotrophin versus recombinant FSH (rFSH) with respect to the prevention of OHSS
Phase:
Phase 4
Details
Lead Sponsor:
Zekai Tahir Burak Women's Health Research and Education Hospital
Treatments:
Menotropins